Skip to main content
OpenTrials
Completed

NCT Number: NCT06579209

NAD+ Oral Supplement Pilot Intervention in Adult Females

The goal of this clinical trial is to learn whether Nicotinamide adenine dinucleotide (NAD+) can influence cognition and biomarkers in healthy, cognitively intact women aged 40-80. The main questions it aims to answer are:

Will cognitive functioning change in response to NAD+? Will inflammatory markers and serum indicators of neurodegeneration change in response to NAD+? Researchers will compare individuals receiving NAD+ to those receiving placebo to see if the results differ.

Participants will:

Complete an online questionnaire, Visit the lab for computerized cognitive testing and a blood draw, Take NAD+ or a placebo every day for 4 weeks, Visit the lab for computerized cognitive testing and a blood draw

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cognitive Change Inflammation Nervous System Diseases Neurodegenerative Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

40 year–80 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

University of Rhode Island, Kingston, Rhode Island, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Identify as Female
  • Have a BMI of 18.5 or above
  • Must be able to swallow tablets

Exclusion criteria

  • Those who are pregnant, breastfeeding, or taking hormone medication

Treatment and study plan

Treatment

Dietary Supplement

Participants will take a supplement for four weeks. The supplement will either be Nicotinamide adenine dinucleotide or a placebo.

Other names: Nicotinamide adenine dinucleotide

Placebo

Other

Participants will take a supplement for four weeks. The supplement will either be Nicotinamide adenine dinucleotide or a placebo pill.

Primary outcomes

  1. Neurocognition

    Time frame: four weeks

    NIH Toolkit Cognition Battery, Automated Neuropsychological Assessment Metrics

  2. Neurodegenerative disease panel

    Time frame: four weeks

    BDNF, Cathespin D, MPO, PAI-1 (total), PDGF-AA, PDGF-AB/BB, RANTES, slCAM-1, sNCAM, sVCAM-1

  3. Markers of systemic inflammation

    Time frame: four weeks

    GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-23, TNFα

Sponsors and collaborators

Lead sponsor

University of Rhode Island

Other

Collaborators

  • National Institute of General Medical Sciences (NIGMS)

Registry information

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Aug 30, 2024
Registry last updated
Mar 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.